Vasalgel is a new male contraceptive being developed by the Parsemus Foundation’s social venture, Revolution Contraceptives, to fill the need for a non-hormonal, long-acting, reversible male method.
- Despite currently available contraceptives, 85 million unintended pregnancies (40%) occur annually worldwide.
- Men currently have little choice when it comes to contraception. Vasectomy is considered permanent, and condoms have a high failure rate with typical use.
- While women have more options, many methods are discontinued due to side effects.
- Men and women are demanding more options for contraception, especially male methods.
- Research shows that about half of men surveyed would be willing to use a new male contraceptive.
- Long-acting, reversible, and non-hormonal methods are preferred.
- The Parsemus Foundation has supported the development of Vasalgel, a long-acting, non-hormonal male contraceptive that is designed to be reversible.
- Vasalgel blocks the flow of sperm from the body with an injection of a gel into the vas deferens.
- Revolution Contraceptives, the social venture company developing Vasalgel, believes in empowering men worldwide to better control their reproduction with a reliable, safe, cost-effective, and reversible contraceptive.
Vasalgel, a multi-year contraceptive
VasalgelTM is being developed as a long-acting, non-hormonal contraceptive with a significant advantage over vasectomy: it is likely to be more reversible. The procedure is similar to a no-scalpel vasectomy, except a gel is injected into the vas deferens (the tube the sperm swim through), rather than cutting the vas (as is done in vasectomy). If a man wishes to restore the flow of sperm, whether after months or years, the polymer would be dissolved and flushed out.
In early 2010, the Parsemus Foundation began developing Vasalgel as a new vas-occlusive polymer contraceptive. Revolution Contraceptives was created to bring the product to market. This social venture company’s mission is to empower men worldwide to better control their reproduction with a reliable, safe, cost-effective, and reversible contraceptive.
Human Health News
The Parsemus Foundation began working on a new male contraceptive called Vasalgel a number of years ago. In 2013, Revolution Contraceptives was formed as a
Research on spaying and neutering has increasingly provided evidence of potential negative effects on lifelong health in dogs. Hormone-sparing sterilization is a way to preserve
The Male Contraceptive Initiative announced that the Youth Advisory Board Undergraduate Project Grant program is accepting applications until September 30, 2021. The grant aims to
One out of every seven cats has hypertrophic cardiomyopathy — a heart disease that causes the heart muscle to thicken. This disease can cause blood